Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /CNW/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New […]

Scroll to top